SMN1 and proximal spinal muscular atrophy: For restoration of protein production affected by variants in monogenic disease, Nusinersen was approved for treatment of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder usually caused by variants in the SMN1 gene [37].